# Barclays

Type: Company (BCS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/barclays
Canonical HTML page: https://getbiobrief.com/entity/barclays

## Recent coverage (2 stories)

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### REGENXBIO CMO Sells $688K Shares After Q1 Miss, Yet Analysts See 99% Upside
2026-07-06 01:38:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Full story: https://getbiobrief.com/story/regenxbio-cmo-sells-688k-after-q1-miss-analyst-upside

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.